D011744Chemicals & DrugsD03.383.742.69821360.968418Pyrimidinonesprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonObstetrics and Gynecology30739822Tang J, Do HT, Huber AD, Casey MC, Kirby KA, Wilson DJ, Kankanala J, Parniak MA, Sarafianos SG, Wang ZEuropean journal of medicinal chemistryPharmacophore-based design of novel 3-hydroxypyrimidine-2,4-dione subtypes as inhibitors of HIV reverse transcriptase-associated RNase H: Tolerance of a nonflexible linker. Eur J Med Chem. 2019 Mar 15; 166:390-399.Eur J Med Chem2019-02-02T00:00:002019Pharmacophore-based design of novel 3-hydroxypyrimidine-2,4-dione subtypes as inhibitors of HIV reverse transcriptase-associated RNase H: Tolerance of a nonflexible linker.ParthModiParth Modi41.7886000000000087.598699999999993949Modi, ParthAssistant ProfessorAymanAl-HendyAyman Al-Hendy41.7886000000000087.598699999999993954Al-Hendy, AymanProfessor33485453Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, Olawaiye AB, Ellard SL, Weberpals JI, Wahner Hendrickson AE, Fleming GF, Welch S, Dhani NC, Stockley T, Rath P, Karakasis K, Jones GN, Jenkins S, Rodriguez-Canales J, Tracy M, Tan Q, Bowering V, Udagani S, Wang L, Kunos CA, Chen E, Pugh TJ, Oza AMLancet (London, England)Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 01 23; 397(10271):281-292.Lancet2021-01-23T00:00:002021Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.Medicine-Hematology and Oncology33596357Al-Hendy A, Lukes AS, Poindexter AN, Venturella R, Villarroel C, Critchley HOD, Li Y, McKain L, Arjona Ferreira JC, Langenberg AGM, Wagman RB, Stewart EAThe New England journal of medicineTreatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021 02 18; 384(7):630-642.N Engl J Med2021-02-18T00:00:002021Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.2.118010.017797121research area of0.977670.024267740subject area forMedicineUniversity of ChicagoRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.ProfessorDavidMeltzerDavid Meltzer41.78927490000000-87.601250000000001882Meltzer, DavidProfessor37863160Stewart EA, Al-Hendy A, Lukes AS, Madueke-Laveaux OS, Zhu E, Proehl S, Schulmann T, Marsh EEAmerican journal of obstetrics and gynecologyRelugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. Am J Obstet Gynecol. 2024 Feb; 230(2):237.e1-237.e11.Am J Obstet Gynecol2023-10-18T00:00:002023Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.DanielWilsonDaniel J. Wilson41.78927490000000-87.601250000000002342Wilson, Daniel38127590Polcari K, Hyman MJ, Skolarus TA, Sales AE, Meltzer DO, Modi PKJAMA health forumIndustry Payments for Vibegron and Prescribing Patterns Among Urologic Clinicians. JAMA Health Forum. 2023 Dec 01; 4(12):e234020.JAMA Health Forum2023-12-01T00:00:002023Industry Payments for Vibegron and Prescribing Patterns Among Urologic Clinicians.true1true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant ProfessorSurgery-Urology